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related to treatment. Regarding the physical symptoms, the 
most frequent complaints were fatigue, alopecia and con-
stipation, while the most troublesome symptoms were nau-
sea, poor taste and paresthesia. Overall, the most frequently 
expressed concerns were ‘affects my family or partner’ and 
anxiety related to treatment. Male patients suffered most 
from fever, fatigue and nausea, and female patients com-
plained more of poor taste and gastrointestinal problems.
Conclusion Patient perceptions of adverse events associ-
ated with cancer chemotherapy apparently have changed 
from physical symptoms to non-physical concerns. In our 
patient cohort ‘affects my family or partner’ was the most 
important concern. One important point to note is that 
female patients often complained of poor taste because this 
meant they were unable to cook well.
Keywords Chemotherapy · Side effects · Pain · Patient 
perceptions
Introduction
Cancer has been a leading cause of death in Japan since 
1981, and one out of two Japanese people develops cancer 
during their life time [1]. Early detection and treatment are 
essential to cure this devastating disease. However, with a 
few exceptions, such as lymphoma, leukemia and germ cell 
tumors, advanced and relapsed cancers are rarely curable 
by any treatment modalities. Even patients who are thought 
be cured have had to go through painful laboratory exami-
nations and treatments consisting of surgery and/or radia-
tion therapy and/or chemotherapy. Surgery and irradiation 
are local treatments that are completed within a couple 
of weeks, and usually only the local adverse sequelae are 
significant. In contrast, chemotherapy is scheduled over 
Abstract 
Background Cancer chemotherapy is associated with a 
variety of side effects/adverse events. It is very important 
that patients adhere to the planned chemotherapy regimen, 
which necessitates a minimum of side effects and that these 
side effects be kept under control. We have investigated 
patients’ concerns and symptoms during chemotherapy 
with the aim to seek solutions that will improve patients’ 
quality of life during chemotherapy.
Methods Forty-nine patients with malignant diseases on 
parenteral antineoplastic agents were sequentially enrolled 
in this study. These patients completed a questionnaire con-
sisting of 42 items related to non-physical concerns and 52 
items of physical symptoms related to chemotherapy. Each 
patient was also asked to select the three items among these 
94 items which affected him/her the most. 
Results The median age of the cancer patients was 62 
years and the male-to-female ratio was 18:31. Among the 
non-physical concerns, the most frequently chosen concern 
was ‘affects my family or partner,’ followed  by anxiety 
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months or even years in some diseases. It is a systemic 
therapy often associated with a variety of side effects and 
can occasionally be life-threatening. The emergence of 
adverse side effects can negatively affect a patient in a vari-
ety of ways. Consequently, there is a need to control such 
side effects since interruption of the chemotherapeutic regi-
men is detrimental to both a high cure rate or prolongation 
of survival with a good quality of life (QoL).
In 1983, an Australian research roup reported patients’ 
perceptions of the side effects of cancer chemotherapy. 
Emesis, nausea and loss of hair were identified as major 
physical symptoms,  and anxiety when coming to treat-
ment, treatment time and fear of needles were major 
non-physical concerns [2]. Ten years later, following the 
introduction of a new group of antiemetics, the 5-hydroxy-
tryptamine 3 (5HT3) receptor antagonists into clinical use, 
the same research group conducted a repeat study using the 
same measures. This time, nausea overtook emesis, which 
ranked fifth in the repeat study, and there was a clear shift 
in patient concerns  from those about physical symptoms to 
psychosocial issues [3]. In 2002, a French group carried out 
a similar survey and found that chemotherapy-induced nau-
sea and vomiting (CINV) was no longer within the top ten 
of patient concerns and that ‘affects my family or partner’ 
ranked first [4].
In Japan, aprepitant, a neurokinin-1 (NK-1) receptor 
antagonist, and palonosetron, a second-generation 5HT3 
receptor antagonist,  were approved for in 2009 and 2010, 
respectively, and their use has gradually spread throughout 
Japan. By 2011 these new antiemetics were routinely used 
in medical practice. It is therefore timely to investigate 




We sequentially selected patients with pathologically docu-
mented malignant disorders who were being treated with 
parenteral antineoplastic agents in our department. All solid 
tumor patients had advanced cancer, and all hematologi-
cal malignancy patients were at advanced stages. Patients 
who had received cytotoxic chemotherapy in the 4-week 
period immediately prior to their interview were included 
in the study. The study was approved by the Fukuoka Uni-
versity Hospital Review Board. A cancer research nurse 
explained the aim and design of the study to the patients. 
Those who consented to participate were asked to complete 
a questionnaire consisting of 94 items on signs and symp-
toms potentially related to chemotherapy. Upon comple-
tion by the patient, the nurse checked whether all answers 
were appropriately filled in and asked the patient to correct 
any entry which was not completed or the answer unclear. 
This questionnaire consisted of two categories of questions, 
group A and group B; for each item of group A the patient 
was asked to choose between yes or no as answer, and 
for the items in group B, the patient was asked to choose 
one of five options, from the worst symptom (grade 4) to 
no complaint (grade 0). The patient was also requested to 
choose the three items that influenced/affected him/her 
most, i.e., the most painful or most troubling events from 
group A, group B, and the entire 94 items. Most patients 
were able to choose three items which were most trouble-
some or painful. Patients who had difficulty in choosing 
three items were offered help from the nurse in the form 
of explanations. These nurses were members of the nurs-
ing staff who had no association with the patients in routine 
clinical practice, and they intervened as little  as possible 
while the patient was filling in the questionnaire.
Creating a questionnaire
To be able to compare the perceptions of our Japanese 
patients with those of patients in Western countries, we 
used the questions covered by Carelle et al.’s study [4], 
which used a questionnaire with items on 45 physical 
symptoms and 27 non-physical concerns. Since there no 
studies on patient perceptions of symptoms and concerns 
who received chemotherapy in Japan have been conducted, 
we had those items translated into Japanese. Some items 
had to be changed and/or added to in order to facilitate 
ease of answering for Japanese people. We changed “physi-
cal concerns” to descriptions easy for Japanese patients to 
understand; for example, for “pain” we added items to each 
specific site. We then rearranged the items in anatomical 
order, again to make it easier for the patient to understand 
the question. For “non-physical concerns”, we changed 
items to correlate better with present-day life in Japan. Spe-
cifically, items of aging, social and economic problems, 
and human relations were modified and/or  added. Finally, 
we added 11 and 26 items for “physical concerns” and 
“non-physical concerns”. Thus, while several items have 
been added to those in questionnaire used in Carelle et al.’s 
study [4], all of their items were included, making it possi-
ble to compare our results with those of previous studies in 
general and Carelle et al.’s study [4] in particular. The ques-
tionnaire which we created consisted of a group of ques-
tions pertaining to non-physical concerns (group A) and a 
group of questions pertaining to physical concerns (group 
B) (Tables 1, 2). Items in both  group A and group B related 
to potential adverse events of chemotherapy. The Japanese 
version of the questionnaire is given in the Electronic Sup-
plementary Material.
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Results
A total of 49 cancer patients receiving chemotherapy 
as an outpatient or an inpatient at Fukuoka University 
Hospital participated in this study during a period of 
6 months from September 2011 to February 2012. The 
background characteristics of these patients are shown 
in Table 3. The median age was 62 (range 32–84) years, 
and the male-to–female ratio was 18:31. There were 21 
patients with hematological malignancies and 28 with 
solid tumors. The anticancer agents used in 36 (74%) 
patients were categorized as highly or moderately eme-
togenic according to the CINV guidelines in Japan [5].
Patients with lymphoma, leukemia and breast cancer 
mainly received an anthracycline-based regimen while 
those with colorectal or lung cancer were treated with 
oxaliplatin or carboplatin combination chemotherapy.
A total of 91 symptoms were noted to be adverse 
events by the patients. Frequent painful non-physical 
concerns were ‘affects my family or partner’ followed in 
order by anxiety about difficulty in recovering from the 
previous chemotherapy, ‘affects my work or housework’, 
sick feeling, dissatisfaction about a change of primary 
care physician, and anxiety while on treatment and others 
(Table 4). The most troublesome non-physical concerns 
were almost the same as the high-frequency non-phys-
ical concerns; top of the list was ‘affects my family or 
partner’ followed by various anxieties and vague fears, 
but it is of note that the cost of medical fees ranked fifth 
(Table 6).
Among the physical symptoms, the most frequent 
complaints were fatigue, alopecia, constipation, loss of 
appetite, and paresthesia (Table 5). More than one-half of 
patients suffered a moderate to severe degree of fatigue, 
alopecia, constipation and loss of appetite. However, the 
most annoying problems were nausea, poor taste and par-
esthesia (9 patients each) followed by fatigue (8 patients), 
and fever and insomnia (7 patients each).
Nine patients complained of nausea as an unbearable 
experience. In five patients the nausea was associated 
with highly to moderately emetogenic anticancer drugs, 
while in the others the nausea was secondary to either 
opioid use, peritonitis carcinomatosa, tumor infiltration 
of the stomach or cerebral hemorrhage.
The clinical signs and symptoms that concerned the 
patients the most in the entire group were ‘affects my 
family or partner’ followed in descending order by anxi-
ety about recovering from the previous treatment for the 
Table 1  Group A items in the questionnaire—non-physical concerns
Please select the three most troubling items from items 1 to 42: (), (), ()
No. of item Concerns No. of item Concerns
1 Forget things 22 When do I have to go to a hospice care facility?
2 Feeling low 23 Cannot get clothes that fit
3 Feeling sick 24 Affects my work/home duties
4 Easily excited 25 Affects my family or partner
5 Cannot move forward 26 Can I return to my normal social life?
6 Losing the will 27 Affects social activity
7 Whimper/crying more often 28 Length of time treatment takes at clinic
8 Irritable 29 Presence of family members I have to take care of
9 Cannot concentrate 30 Cannot eat raw foods
10 Feeling fearful 31 Can I get married?
11 Fear of death 32 Effects delivery or infants or raising my children
12 Hard to understand what is going on 33 Infertility
13 Feeling anxious about treatment 34 Loss of sexual ability
14 Feeling anxious about being unable to recover from the previous 
therapy
35 Travel time to come to the hospital
15 Feeling anxious about my life 36 Medical costs
16 No adviser 37 Relationships with medical staff
17 No supporter 38 Relationships with other patients
18 I do not want others to know about my disease 39 Problem with the hospital
19 Changing the primary physician 40 Contact methods for medical staff
20 Can I trust information on the internet? 41 Can I call medical staff when I am sick?
21 Hesitant to ask my primary physician to get a second opinion 42 Others ()
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next therapy, anxiety about treatment, nausea, poor taste, 
numbness, fatigue, vague fears and so on (Table 6).
There was no difference in symptoms between female 
and male patients for non-physical concerns, but for physi-
cal symptoms male patients suffered most from fever, 
fatigue and nausea, while females complained of poor 
taste, nausea, stomatitis, paresthesia, vomiting, and diar-
rhea (Table 7). Female patients felt that gastrointesti-
nal problems were the most problematic side effects of 
chemotherapy.
Discussion
It is important to understand not only the significant physi-
cal symptoms but also non-physical concerns that patients 
feel or suffer from during systemic cancer therapy. Patients 
undergoing cancer chemotherapy can be made more 
comfortable by reducing the incidence and the severity 
of adverse events and by providing an appropriate dose 
and schedule of antineoplastic agents that will result in 
maximum antitumor effects with an improvement in QoL 
and survival.
In the early evolution of cancer chemotherapy in the 
1970s and 1980s, severe CINV and emesis and nausea 
ranked first and second as the most troubling symptoms of 
cancer chemotherapy [2]. CINV in some patients was so 
serious that they refused to continue on their chemothera-
peutic regimen despite the underlying disease being poten-
tially curable. The situation improved with the approval of 
the 5HT-3 receptor antagonist as a prophylaxis for CINV in 
the 1990s, followed by the introduction of the NK-1 recep-
tor antagonist at the beginning of the twenty-first century. 
The results of our study indicate that from the perspective 
of total management of cancer chemotherapy, CINV no 
longer ranks as a top concern among cancer patients under-
going chemotherapy.
Carelle et al. [4] reported a change in patient perceptions 
of the side effects of cancer chemotherapy. These authors 
found that ‘Affects my family or partner’ was ranked first, 
followed by anxieties and fears about a variety of events 
and non-physical concerns like ‘affects my work’ and 
Table 2  Group B items in 
the questionnaire—physical 
symptoms
Please select the three most troubling items from 43 to 94: (), (), ()
No. of item Concerns No. of item Concerns
43 Nausea 69 Pain during urination
44 Emesis 70 Difficulty in urination
45 Constipation 71 Nasal bleeding
46 Diarrhea 72 Headache
47 Change in the way things taste 73 Dizziness
48 Taste nothing 74 Giddiness on standing up
49 Poor appetite 75 Ringing in ears
50 Sore throat 76 Difficulty in hearing
51 Abdominal pain 77 Bruise easily
52 Abdominal distension 78 Urticaria/wheals
53 Dry mouth 79 Change in skin color
54 Change in how things smell 80 Change in nails (color, pain, breaks)
55 Stomatitis/sore mouth 81 Hot flush
56 Increase appetite 82 Acne (pimples) or eczema
57 Cheilosis 83 Dry skin
58 Difficulty in swallowing 84 Itching
59 Numbness (Which part of body?) 85 Dermatitis sensitive to sun
60 Pain in fingers and/or toes 86 Fever
61 Dulling of senses 87 Fatigue
62 Tingling sensation (Which part of body?) 88 Alopecia/loss of hair
63 Pain at injection site 89 Weight loss
64 Poor veins 90 Weight gain
65 Anthralgia 91 Edema
66 Myalgia 92 Palpitation
67 Colored urine 93 Shortness of breath
68 Amount of urine 94 Insomnia
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medical costs. The results of our are in agreement with 
those of study agreed with those reported by Carelle et al. 
[4]: ‘affects my family or partner’ was the most important 
concern of all 94 items in the questionnaire. This result 
suggests that patient perceptions of the side effects or 
experiences during systemic chemotherapy have shifted 
markedly from the physical symptoms, especially from 
CINV, to non-physical concerns.
For physical symptoms, the number of patients with 
symptoms in general and number of patients with the most 
painful symptoms were similar. However, the significant 
difference in complaints about physical symptoms between 
male and female patients was of interest. Female patients 
complained of difficulty in tasting foods properly, nau-
sea, stomatitis, and dysesthesia, while male patients suf-
fered most from fever and fatigue. Female patients felt that 
gastrointestinal problems were the most problematic side 
effects of chemotherapy. Women in Japan are still the pre-
dominant preparer of meals for their family, but gastroin-
testinal symptoms would seem to preclude the preparation 
of meals. In particular, difficulty in appreciating sweetness 
and saltiness properly makes it difficult for a housewife to 
prepare palatable food by checking the taste during cook-
ing. Compared with men, women experience CINV more 
frequently and to a more severe degree [6].
Fatigue was the most frequent symptom reported among 
all physical symptoms, as shown in Table 5, not only by 
male patients but also by female patients. It is not easy 
for patients to differentiate chemotherapy-induced fatigue 
from fatigue due to their advanced underlying disease, and 
this study was not designed to address that distinction [7]. 
Anemia is a treatable pathophysiological state that induces 
fatigue and weakness. It has been treated with erythro-
poietin in Western countries, and improvement of anemia 
alleviates profound fatigue [8], but erythropoietin is not 
approved for cancer-related anemia in Japan. Considering 
the incidence and severity of fatigue in cancer patients on 
chemotherapy, it is to be hoped that erythropoietin will be 
approved for clinical use in the Japanese oncology field.
As shown in Table 6, concerns about their patient’s 
family or partner and anxiety related to treatment were 
the top three complaints among our cancer patients, 
Table 3  Patient demographics and clinical characteristics
Values in table are presented as the median with the range in square 
brackets or as a number
Characteristics Value
No. of patients 49
Age (years) 62 [32–84]
Gender
  Male 18
  Female 31
Disease types
  Hematological malignancy 21
    Malignant lymphoma 10
    Multiple Myeloma 4
    Acute leukemia 5
    Others 2
  Solid tumor 28
    Breast 9
    Colorectal 5
    Esophagus 3
    Stomach 3
    Lung 2
    Others 6
Emetic risk
  High 16
  Moderate 20
  Low 7
  Minimal 6
Table 4  Non-physical concerns 
noted by patients
Non-physical concerns No. of patients (%)
Affects my family or partners 32 (65)
Feeling anxious about being unable to recover from the previous treatment 31 (63)
Affects on my work/home duties 26 (53)
Feeling sick 25 (51)
Changing the primary physician 25 (51)
Feeling anxious about the treatment 22 (45)
Feeling low 21 (43)
Feeling fearful 21 (43)
Medical costs 21 (43)
Losing the will 20 (41)
Fear of death 19 (39)
Feeling anxious about my life 18 (37)
Can return to a normal social life? 18 (37)
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indicating an apparent shift from concerns regard-
ing physical symptoms to psychosocial issues. These 
issues are quite subjective and difficult to measure even 
by appropriate instruments or tools. Therefore, unless 
patients express their concerns to medical staff, they may 
be easily overlooked or even ignored by healthcare pro-
viders. Our data and the results from a series of studies 
by an Australian group suggest the necessity of thorough 
physical symptoms and non-physical examinations before 
the start of chemotherapy. If a significant problem or con-
cern is raised, it may have to be solved before treatment; 
otherwise, it may lead to an early interruption of the treat-
ment and subsequent poor outcome.
Patient perceptions of the side effects of cancer chem-
otherapy based on the analysis of a thorough question-
naire have not previously been reported for Japanese 
patients. Yokoo et al. [9] carried out an Internet survey 
in which cancer patients’ concerns and their associations 
with QoL were assessed; 807 patients with all types of 
cancer who were older than 20 years participated in the 
survey, but no information on treatment was available. 
These authors reported that concerns about ‘self-man-
agement’ was the most common (61%) reported concern, 
followed by psychological symptoms (48%), medical 
information (46%), daily living (30%). Unfortunately 
concerns about family or partner were not included in 
this survey questionnaire. However, this Internet survey 
did illustrate that cancer patients in general seem to place 
a special emphasis on non-physical concerns rather than 
physical symptoms.
Patients experience a variety of side effects associ-
ated with chemotherapy. A major question to be asked by 
healthcare providers is whether chemotherapy is really 
good for patients in terms of QoL. In a prospective rand-
omized phase three trial Dancey et al. [10] observed the 
superiority of second-line docetaxel over best supportive 
care in patients with lung cancer. The Australian–New Zea-
land Breast Cancer Trials Group conducted a study com-
paring continuous treatment with intermittent therapy in 
Table 5  Physical symptoms noted by patients
Values in table are presented as the number of patients with the per-
centage in parenthesis
a
 0, No symptoms; 1, minimal symptoms; 2, mild symptoms; 3, mod-
erate symptoms; 4, severe symptoms
Physical symptoms Grade of  symptoma
4 3 2 1 0
Fatigue 7 (14) 13 (26) 10 (20) 6 (12) 13
Alopecia 18 (36) 6 (12) 4 (8) 4 (8) 17
Constipation 6 (12) 10 (20) 10 (20) 5 (10) 18
Loss of appetite 10 (20) 10 (20) 7 (14) 3 (6) 20
Paresthesia 10 (20) 5 (10) 5 (10) 8 (16) 21
Loss of weight 9 (18) 5 (10) 4 (8) 9 (18) 22
Shortness of breath 3 (6) 5 (10) 9 (18) 10 (20) 22
Stomatitis 5 (10) 2 (4) 5 (10) 15 (30) 22
Change in the way things 
taste
8 (16) 8 (16) 5 (10) 5 (10) 23
Dry skin 4 (8) 4 (8) 11 (22) 7 (14) 23
Insomnia 4 (8) 7 (14) 8 (16) 7 (14) 23
Nausea 6 (12) 2 (4) 6 (12) 10 (20) 25
Taste nothing 7 (14) 9 (18) 3 (6) 5 (10) 25
Fever 5 (10) 6 (12) 7 (14) 6 (12) 25
Table 6  Most serious concerns 
selected by patients from among 
all physical and non-physical 
concerns
Rank Most serious concerns No. of patients (%)
1 Affects my family or partner 18 (36)
2 Feeling anxious about being unable to recover from the previous therapy 13 (26)
3 Feeling anxious about treatment 10 (20)
4 Nausea 9 (18)
4 Change in the way things taste 9 (18)
4 Numbness 9 (18)
7 Fatigue 8 (16)
8 Feeling fearful 7 (14)
8 Medical costs 7 (14)
8 Fever 7 (14)
8 Insomnia 7 (14)
12 Fear of death 6 (12)
12 Anxiety to return to work 6 (12)
12 Diarrhea 6 (12)
12 Loss of appetite 6 (12)
12 Pain at infection site 6 (12)
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women with advanced breast cancer [11]. If disease did not 
progress in the patients receiving intermittent therapy, the 
treatment was withheld after three cycles. The same treat-
ment was restarted only after the disease progressed, at 
which time three cycles were again given. This sequence 
was repeated until the disease no longer responded to the 
treatment. The survival did not differ significantly between 
the arms, but the QoL was worse in patients assigned to 
intermittent rather than continuous therapy, suggesting that 
QoL was improved by inducing and maintaining a tumor 
response despite the occurrence of side effects associated 
with chemotherapy.
A major limitation to our study is the small number of 
patients compared to previous studies, so it is difficult to 
draw comparisons for each gender, chemotherapy regimen, 
or disease, and in particular it is impossible to make sta-
tistical comparisons. However, in this study, 94 items per-
tinent to cancer patients undergoing chemotherapy were 
surveyed using a questionnaire, and important data on Jap-
anese patients’ perception of concerns in this setting were 
obtained for the first time.
In conclusion, patient perceptions of adverse events 
associated with cancer chemotherapy have apparently 
shifted from physical symptoms to non-physical concerns. 
‘Affects my family or partner’ is now the most important 
concern. A multi-disciplinary approach that includes the 
active involvement of medical social workers and medical 
staff is necessary to minimize their suffering. One inter-
esting factor that appears not to have been noticed previ-
ously—or ignored—is the poor taste perception in female 
patients. This is particularly significant for Japanese 
women but has not been raised by women in Western stud-
ies, suggesting that the cultural background of the patient 
influences his/her perception of signs and symptoms asso-
ciated with cancer treatment.
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